Common Contracts
28 similar null contracts by Aemetis, Inc, Customers Bancorp, Inc., Eco-Stim Energy Solutions, Inc., others
ENDRA LIFE SCIENCES INC. Common Stock (par value $0.0001 per share) At-The- Market Issuance Sales AgreementENDRA Life Sciences Inc. • February 14th, 2024 • Electromedical & electrotherapeutic apparatus • New York
ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Ascendiant Capital Markets, LLC and the other sales agents set forth on Annex 1 hereto (each, an “Agent” and, collectively, the “Agents”), as follows:
CURIS, INC. Common Stock ($0.01 par value per share) Amended and Restated Sales AgreementCuris Inc • February 8th, 2024 • Biological products, (no disgnostic substances) • New York
Curis, Inc., a Delaware corporation (the “Company”) and Cantor Fitzgerald & Co. (“Cantor”) and JonesTrading Institutional Services LLC (“JonesTrading”; each of Cantor and JonesTrading individually an “Agent” and collectively, the “Agents”) are parties to that certain Sales Agreement, dated March 16, 2021, as amended by Amendment No. 1 to Sales Agreement, dated August 12, 2022 (together, the “Original Agreement”). Each of the Agents and the Company desire to amend and restate the Original Agreement as set forth in this agreement (the “Agreement”), and hereby agree as follows:
Enlivex Therapeutics Ltd. Ordinary Shares (par value NIS0.40 per share) Controlled Equity OfferingSM Sales AgreementEnlivex Therapeutics Ltd. • December 30th, 2022 • Pharmaceutical preparations • New York
Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. and JMP Securities LLC (collectively, the “Agents”), as follows:
SACHEM CAPITAL CORP. Common Stock ($0.001 par value per share) At Market Issuance Sales AgreementSachem Capital Corp. • December 7th, 2021 • Real estate investment trusts • New York
Sachem Capital Corp., a New York corporation (the “Company”), confirms its agreement (this “Agreement”), with Ladenburg Thalmann & Co (“Ladenburg”) and Janney Montgomery Scott LLC (“Janney”, each of Ladenburg and Janney, individually an “Agent” and collectively, the “Agents”), as follows:
AEMETIS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAemetis, Inc • October 1st, 2020 • Industrial organic chemicals • New York
Aemetis, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (“HCW”) and Roth Capital Partners, LLC (“ROTH”; each of HCW and ROTH individually a “Distribution Agent” and collectively the “Distribution Agents”) as follows:
SACHEM CAPITAL CORP. Common Stock ($0.001 par value per share) At Market Issuance Sales AgreementSachem Capital Corp. • July 2nd, 2019 • Real estate investment trusts • New York
Sachem Capital Corp., a New York corporation (the “Company”), confirms its agreement (this “Agreement”), with Janney Montgomery Scott LLC (“Janney”) and Ladenburg Thalmann & Co (“Ladenburg”, each of Janney and Ladenburg, individually an “Agent” and collectively, the “Agents”), as follows:
At Market Issuance Sales AgreementConatus Pharmaceuticals Inc. • August 2nd, 2018 • Pharmaceutical preparations • New York
Conatus Pharmaceuticals Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel”), as follows:
par value $0.01 per share) At Market Issuance Sales AgreementITUS Corp • September 29th, 2017 • Patent owners & lessors • New York
ITUS Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”) as follows:
PARKERVISION, INC.Parkervision Inc • August 14th, 2017 • Radio & tv broadcasting & communications equipment • New York
ParkerVision, Inc., a Florida corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”) as follows:
AT MARKET ISSUANCE SALES AGREEMENTSpectrum Pharmaceuticals Inc • August 4th, 2017 • Pharmaceutical preparations • New York
Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co. LLC (“HCW”), FBR Capital Markets & Co. (“FBR”) and MLV & Co. LLC (“MLV”, each of HCW, FBR and MLV, individually a “Distribution Agent” and collectively, the “Distribution Agents”) as follows:
ACTINIUM PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementActinium Pharmaceuticals, Inc. • March 16th, 2017 • Pharmaceutical preparations • New York
At Market Issuance Sales AgreementParkervision Inc • December 30th, 2016 • Radio & tv broadcasting & communications equipment • New York
ParkerVision, Inc., a Florida corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”) as follows:
At Market Issuance Sales AgreementCustomers Bancorp, Inc. • August 11th, 2016 • State commercial banks • New York
Customers Bancorp, Inc., a Pennsylvania corporation (the "Company"), confirms its agreement (this "Agreement"), with FBR Capital Markets & Co. ("FBR"), Keefe, Bruyette & Woods, Inc. ("KBW") and Maxim Group LLC ("Maxim", each of FBR, KBW and Maxim, individually a "Distribution Agent", collectively, the "Distribution Agents") as follows:
At Market Issuance Sales AgreementEco-Stim Energy Solutions, Inc. • July 14th, 2016 • Oil & gas field services, nec • New York
BELLEROPHON THERAPEUTICS, INC.Bellerophon Therapeutics, Inc. • May 27th, 2016 • Pharmaceutical preparations • New York
Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”) and MLV & Co. LLC (“MLV”, each of FBR and MLV individually a “Distribution Agent” and collectively the “Distribution Agents”) as follows:
FORM OF ECO-STIM ENERGY SOLUTIONS, INC. Common Stock (par value $0.001 per share)Eco-Stim Energy Solutions, Inc. • May 3rd, 2016 • Oil & gas field services, nec • New York
AEMETIS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAemetis, Inc • March 29th, 2016 • Industrial organic chemicals • New York
Aemetis, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”) and MLV & Co. LLC (“MLV”; each of FBR and MLV individually a “Distribution Agent” and collectively the “Distribution Agents”) as follows:
AMYRIS, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales AgreementAmyris, Inc. • March 9th, 2016 • Industrial organic chemicals • New York
Amyris, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”) and MLV & Co. LLC (“MLV”, each of FBR and MLV individually a “Distribution Agent” and collectively the “Distribution Agents”) as follows:
At Market Issuance Sales AgreementCustomers Bancorp, Inc. • December 23rd, 2015 • State commercial banks • New York
Customers Bancorp, Inc., a Pennsylvania corporation (the "Company"), confirms its agreement (this "Agreement"), with FBR Capital Markets & Co. ("FBR"), MLV & Co. LLC ("MLV") and Maxim Group LLC ("Maxim", each of FBR, MLV and Maxim, individually a "Distribution Agent", collectively, the "Distribution Agents") as follows:
AT MARKET ISSUANCE SALES AGREEMENTSpectrum Pharmaceuticals Inc • December 23rd, 2015 • Pharmaceutical preparations • New York
Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”), MLV & Co. LLC (“MLV”), and H.C. Wainwright & Co. LLC (“HCW”, each of FBR, MLV, and HCW, individually a “Distribution Agent” and collectively, the “Distribution Agents”) as follows:
At Market Issuance Sales AgreementBiota Pharmaceuticals, Inc. • October 2nd, 2015 • Biological products, (no disgnostic substances) • New York
Biota Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”) and FBR Capital Markets & Co. (“FBR”; each of MLV and FBR individually a “Distribution Agent” and collectively the “Distribution Agents”) as follows:
At-the-Market Issuance Sales AgreementAnadigics Inc • August 26th, 2015 • Semiconductors & related devices • New York
KINGOLD JEWELRY, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementKingold Jewelry, Inc. • November 19th, 2014 • Services-business services, nec • New York
Kingold Jewelry, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
At Market Issuance Sales AgreementPizza Inn Holdings, Inc /Mo/ • October 1st, 2014 • Wholesale-groceries & related products • New York
Pizza Inn Holdings, Inc., a Missouri corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
INSPIREMD, INC. Common Stock (par value $0.0001 per share) At-the-Market Issuance Sales AgreementInspireMD, Inc. • October 24th, 2013 • Surgical & medical instruments & apparatus • New York
ACURA PHARMACEUTICALS, INC. Common Stock (par value $0.01 per share) At Market Issuance Sales AgreementAcura Pharmaceuticals, Inc • April 18th, 2013 • Pharmaceutical preparations • New York
Acura Pharmaceuticals, Inc., a New York corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
At Market Issuance Sales AgreementPluristem Therapeutics Inc • December 26th, 2012 • Biological products, (no disgnostic substances) • New York
Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
PARAMOUNT GOLD AND SILVER CORP. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement June 23, 2011Paramount Gold & Silver Corp. • June 27th, 2011 • Metal mining • New York
Paramount Gold and Silver Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC (the “MLV”), as follows:
